|
Re: Epigenetics: an exciting new approach in prostate cancer
|
4
|
Zenith Epigenetics
|
Apr 10, 2019 09:15AM
|
|
Re: Epizyme market cap $750 mil USd
|
2
|
Zenith Epigenetics
|
Jun 15, 2017 11:21PM
|
|
Re: Equity financing
|
7
|
Zenith Epigenetics
|
Jun 07, 2018 05:03PM
|
|
Re: Equity financing
|
2
|
Zenith Epigenetics
|
Jun 07, 2018 09:14AM
|
|
Re: ERA-EDTA 2019 June 13-16
|
3
|
Resverlogix Corp.
|
Jun 12, 2019 07:57PM
|
|
Re: ERA-EDTA 2019 June 13-16
|
3
|
Resverlogix Corp.
|
Jun 12, 2019 08:09PM
|
|
Re: ERA-EDTA 2019 June 13-16
|
2
|
Resverlogix Corp.
|
Jun 14, 2019 09:14AM
|
|
Re: ERA-EDTA 2019 Symposium: Vascular calcification in kidney disease: Epigenetics as a novel approach?
|
9
|
Resverlogix Corp.
|
Jul 05, 2019 04:46PM
|
|
Re: ERA-EDTA 2019 Symposium: Vascular calcification in kidney disease: Epigenetics as a novel approach?
|
4
|
Resverlogix Corp.
|
Apr 14, 2019 06:17PM
|
|
Re: ERA-EDTA 2019 Symposium: Vascular calcification in kidney disease: Epigenetics as a novel approach?
|
4
|
Resverlogix Corp.
|
May 29, 2019 05:07PM
|
|
Re: ERA-EDTA posters
|
2
|
Resverlogix Corp.
|
May 24, 2018 08:46AM
|
|
Re: ESC 2016 Symposium
|
2
|
Resverlogix Corp.
|
Jun 15, 2016 01:53PM
|
|
Re: ESC 2017
|
4
|
Resverlogix Corp.
|
Oct 09, 2017 11:52AM
|
|
Re: ESC 2017
|
5
|
Resverlogix Corp.
|
Oct 20, 2017 10:17AM
|
|
Re: ESC 2017 Abstracts are up
|
1
|
Resverlogix Corp.
|
Aug 24, 2017 12:17PM
|
|
Re: ESC 2018 Symposium
|
2
|
Resverlogix Corp.
|
Jun 21, 2018 05:04PM
|
|
Re: ESC 2019 Symposium: Epigenetics: A new pathway to tackle residual risk?
|
5
|
Resverlogix Corp.
|
Jul 06, 2019 12:47PM
|
|
Re: ESC Poster on BETonMACE Design and Baseline Data
|
2
|
Resverlogix Corp.
|
Sep 03, 2019 09:44AM
|
|
Re: ESC Poster on Vascular Inflammation, Calcification and Plaque Vulnerability
|
5
|
Resverlogix Corp.
|
Sep 03, 2019 12:08PM
|
|
Re: ESC Poster on Vascular Inflammation, Calcification and Plaque Vulnerability
|
3
|
Resverlogix Corp.
|
Sep 03, 2019 05:09PM
|
